Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: RGS5

Gene summary for RGS5

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

RGS5

Gene ID

8490

Gene nameregulator of G protein signaling 5
Gene AliasMST092
Cytomap1q23.3
Gene Typeprotein-coding
GO ID

GO:0007154

UniProtAcc

O15539


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
8490RGS5P23T-EHumanEsophagusESCC3.93e-021.85e+000.108
8490RGS5P94T-EHumanEsophagusESCC1.64e-021.72e+000.0879
8490RGS5P104T-EHumanEsophagusESCC4.20e-051.28e+000.0931
8490RGS5HCC1_MengHumanLiverHCC2.12e-04-1.42e-010.0246
8490RGS5HCC5HumanLiverHCC3.69e-095.00e-020.4932
8490RGS5Pt13.aHumanLiverHCC8.83e-197.26e-010.021
8490RGS5Pt13.bHumanLiverHCC7.93e-341.18e+000.0251
8490RGS5Pt13.cHumanLiverHCC2.01e-127.21e-010.0076
8490RGS5Pt14.bHumanLiverHCC7.51e-058.49e-010.018
8490RGS5Pt14.dHumanLiverHCC1.26e-196.62e-010.0143
8490RGS5C43HumanOral cavityOSCC1.43e-06-3.78e-010.1704
8490RGS5C46HumanOral cavityOSCC9.00e-05-3.77e-010.1673
8490RGS5C08HumanOral cavityOSCC8.31e-06-3.76e-010.1919
8490RGS5C09HumanOral cavityOSCC1.13e-02-3.73e-010.1431
8490RGS5NEOLP-2HumanOral cavityNEOLP1.13e-055.96e-01-0.0196
8490RGS5NEOLP-3HumanOral cavityNEOLP5.04e-045.73e-01-0.0191
8490RGS5SYSMH1HumanOral cavityOSCC1.90e-10-3.85e-010.1127
8490RGS5SYSMH2HumanOral cavityOSCC6.00e-07-3.77e-010.2326
8490RGS5SYSMH3HumanOral cavityOSCC9.03e-10-3.86e-010.2442
8490RGS5SYSMH4HumanOral cavityOSCC2.91e-07-3.85e-010.1226
Page: 1 2 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
GCThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CAG: Chronic atrophic gastritis
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
CSG: Chronic superficial gastritis
GC: Gastric cancer
SIM: Severe intestinal metaplasia
WIM: Wild intestinal metaplasia
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
RGS5SNVMissense_Mutationc.509N>Ap.Ser170Tyrp.S170YO15539protein_codingdeleterious(0)probably_damaging(1)TCGA-A8-A09Q-01Breastbreast invasive carcinomaFemale>=65III/IVHormone TherapyanastrozoleSD
RGS5SNVMissense_Mutationc.505N>Ap.Asp169Asnp.D169NO15539protein_codingdeleterious(0)probably_damaging(0.999)TCGA-AR-A0U3-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinSD
RGS5insertionIn_Frame_Insnovelc.269_270insTATCCAACTTCAGACATTCTTAGATGTGGGACTTTGGGCp.Asn90_Leu91insIleGlnLeuGlnThrPheLeuAspValGlyLeuTrpAlap.N90_L91insIQLQTFLDVGLWAO15539protein_codingTCGA-BH-A0AY-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapySD
RGS5SNVMissense_Mutationc.482G>Cp.Arg161Thrp.R161TO15539protein_codingdeleterious(0.02)possibly_damaging(0.814)TCGA-Q1-A73P-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
RGS5SNVMissense_Mutationnovelc.160N>Cp.Ser54Prop.S54PO15539protein_codingtolerated(0.06)benign(0.053)TCGA-AZ-5407-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
RGS5SNVMissense_Mutationrs758639664c.518N>Ap.Arg173Hisp.R173HO15539protein_codingdeleterious(0)probably_damaging(0.999)TCGA-CA-6717-01Colorectumcolon adenocarcinomaMale<65I/IIChemotherapyoxaliplatinCR
RGS5SNVMissense_Mutationrs767246365c.184C>Tp.Arg62Cysp.R62CO15539protein_codingdeleterious(0.03)possibly_damaging(0.79)TCGA-CK-4951-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
RGS5deletionFrame_Shift_Delc.269delNp.Asn90ThrfsTer44p.N90Tfs*44O15539protein_codingTCGA-AD-A5EJ-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
RGS5insertionFrame_Shift_Insnovelc.88_89insTAp.Pro30LeufsTer54p.P30Lfs*54O15539protein_codingTCGA-AM-5820-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
RGS5insertionFrame_Shift_Insnovelc.87_88insTTp.Pro30PhefsTer54p.P30Ffs*54O15539protein_codingTCGA-AM-5820-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
8490RGS5NAirinotecanIRINOTECAN25069475
8490RGS5NAbevacizumabBEVACIZUMAB25069475
8490RGS5NAfluorouracilFLUOROURACIL25069475
8490RGS5NAleucovorinLEUCOVORIN25069475
Page: 1